Reportable Segment Information

12 Months Ended

Sep. 30, 2021

Segment Reporting [Abstract]

Reportable Segment Information

13.  Reportable Segment Information

Reportable segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. We operate two reportable segments:

• Medical Device: Manufacture of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices; drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and structural heart, among others; and the manufacture of interventional medical devices, including drug-coated balloons and mechanical thrombectomy devices, for peripheral arterial disease treatment and other applications; and

• In Vitro Diagnostics: Manufacture of component products and technologies for diagnostic immunoassay as well as molecular test and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

Segment revenue, operating income (loss), and depreciation and amortization were as follows:

	Fiscal Year
(In thousands)	2021			2020			2019
Revenue:
Medical Device	$	78,253		$	71,401		$	78,353
In Vitro Diagnostics		26,883			23,463			21,724
Total revenue	$	105,136		$	94,864		$	100,077
Operating income (loss):
Medical Device	$	4,683		$	(3,246	)	$	4,794
In Vitro Diagnostics		13,770			11,771			10,620
Total segment operating income		18,453			8,525			15,414
Corporate		(11,750	)		(9,776	)		(8,945	)
Total operating income (loss)	$	6,703		$	(1,251	)	$	6,469
Depreciation and amortization:
Medical Device	$	7,224		$	6,223		$	5,811
In Vitro Diagnostics		395			483			464
Corporate		398			557			1,037
Total depreciation and amortization	$	8,017		$	7,263		$	7,312

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

Revenue by geographic region was as follows:

	Fiscal Year
	2021			2020			2019
Domestic		79	%		78	%		81	%
Foreign		21	%		22	%		19	%

Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows:

	September 30,
(In thousands)	2021		2020
U.S.	$	25,920	$	25,273
Ireland		41,224		18,113